Bull & Bear
Bull and Bear
Verdict: Lean Long, Wait For Confirmation — the valuation cushion is real but Q1 FY2026 just contradicted the operating-leverage thesis, so this is a sized-after-Q2 trade, not a buy-now trade.
Bull and Bear are arguing different time frames about the same balance sheet. Bull is right that YSG trades at 0.24× EV/Sales with $151M of cash, zero financial debt, and three institutional cohorts — the founder, Trustar, and Hillhouse — underwriting at a $4.63 ADS conversion price [1] against a $3.17 print. Bear is right that the FY2025 "non-GAAP turn" was half goodwill-bath optics, that Q1 FY2026 operating-loss margin widened to -9.7% on higher Douyin traffic-acquisition costs [3], and that both reportable segments still lost money in FY2025 (Color -¥59M, Skincare -¥31M) [5]. The decisive variable — durable, not headline — is whether the skincare gross-margin mix actually drops to operating margin or gets extracted by platform traffic costs. The Q2 FY2026 print is the proximate test; the answer to that question is what changes the rating, not the size of the next quarterly beat.
Bull Case
The strongest bull case is balance-sheet and mix-driven, not earnings-driven. The cheapest evidence carried forward is the $4.63 conversion price on the March 11, 2026 Trustar/Huang Note Purchase Agreement [1] — a 46% premium to today's $3.17 — combined with Hillhouse, the largest outside holder, ultimately joining the same first closing on equal terms after raising its objection [2]. Three institutional cohorts wrote checks at the same $4.63 strike inside sixty days of today's market price. That is the price anchor; the operating story is the optionality on top.
Bull's price target: $6.50 per ADS over 12–18 months, derived from an EV/Sales rerate to 0.6× on FY2027 consensus revenue (~$816M), still a 70% discount to Proya's ~2×; cross-checked by the $4.63 convertible strike as a smart-money floor and ~$4.60 book value per ADS as downside support. Primary catalyst: FY2026 20-F (printing Feb/Mar 2027) shows skincare segment operating profit turning positive. Disconfirming signal: a third consecutive Q4 goodwill impairment (most likely the ¥134M residual DR.WU goodwill — the FY2024 critical audit matter), or FY2026 full-year non-GAAP operating margin worse than FY2025's -2.0%, confirming Q1 FY2026 as run-rate.
The point dropped from Bull's draft was the buyback-driven cap-table consolidation. It is real (40.2M ADSs retired for $202M; founder voting share 63.8% → 90.7% post-buyback) but it cuts both ways — the same mechanic that thins the float is what gives the founder unilateral control over the related-party convertible the Bear cites. It is not load-bearing for the upside case.
Bear Case
The Bear's strongest evidence is forensic and contemporaneous, not philosophical. The cleanest single piece is that the Q4 FY2025 release discloses RMB 14.6M of out-of-period adjustments swept into the quarter, of which RMB 7.4M relates to prior years — larger than Q4 GAAP net income (RMB 3.0M) and roughly the size of the full-year non-GAAP "profit" itself [4]. And the Q1 FY2026 release names traffic-acquisition costs on the Douyin platform as the operating-margin swing factor [3]. The FY2025 "turn" looked like the residue of a goodwill bath and a widened non-GAAP definition; ninety days later, the gloss came off.
Bear's downside target: $1.75 per ADS over 12 months — EV/Sales compression from 0.24× to 0.10× on FY2026E revenue (~$650M), plus net cash ~$150M, minus $120M convertible-note overhang at face = ~$95M equity / ~95M fully-diluted ADS; cross-checked at 0.4× P/B implying ~$1.80. Primary trigger: Q2 FY2026 print (August 2026) shows operating-loss margin still wider than -5% with S&M intensity above 70%. Cover signal: two consecutive quarters (Q2 + Q3 FY2026) of positive GAAP operating income with S&M intensity below 65% — the platform-cost problem solved and skincare mix earning its margin live. Related-party purchase escalation [6] and the drained balance sheet [7] frame why the convertible is read as forced, not chosen.
The point dropped from the Bear's draft was the structural sub-scale argument. It is true that YSG is 2.5× smaller than Proya and converts 78.2% gross margin to -4.3% operating margin while Proya converts 73.3% to 17.6% [8]. But "small" is not the same as "uninvestable"; the durable bear case is the Q1 reversal and the governance discount, not size.
The Real Debate
Three tensions remain after both advocates rest. Each is the same observed fact read two ways — and each can be settled by an observable, near-record outcome.
The middle tension is the load-bearing one. The other two — bookkeeping versus turn, smart-money versus self-deal — frame the past and the cap table. The Q1 FY2026 Douyin-cost mechanic [3] is what the thesis depends on going forward: does an 80%+ gross margin actually flow to the operating line, or does the channel keep taking it back?
Verdict
Lean Long, Wait For Confirmation. Bull carries more weight on the static picture — at $295M of equity with $151M of cash, zero financial debt, $120M of incoming convertible proceeds underwritten at $4.63 by the people closest to the business, and book value per ADS near $4.60, the downside math is genuinely cushioned and the market is paying near zero for an operating business that just printed an 80.2% gross margin on +58.5% skincare growth. The single most important tension is whether Q1 FY2026's Douyin-driven margin reversal [3] is one-quarter noise or the new run-rate, and on that question the Bear is not provably wrong — Proya's 17.6% operating margin on a similar 73% gross margin [8] is anchored by Tmall category leadership Yatsen has not yet demonstrated, and the FY2025 segment-level losses [5] say the brands have not yet earned their own keep. The condition that would change the verdict to Lean Long (full weight) is the durable thesis variable: FY2026 full-year non-GAAP operating margin better than FY2025's -2.0% with skincare segment operating loss narrower than FY2025's -¥31M — that combination proves the gross-margin lever drops to the operating line. The near-term marker that would let a position be sized is narrower: Q2 FY2026 (August 2026) operating-loss margin back inside -5% and S&M intensity below 70%. If Q2 stays at Q1's shape, the read flips to Watchlist and waits for cleaner evidence than the next quarter.
Lean Long, Wait For Confirmation — Valuation cushion and $4.63 smart-money anchor are real, but the Q1 FY2026 Douyin-cost reversal directly contradicts the operating-leverage thesis. Size after Q2 FY2026 (August 2026) confirms or refutes the channel mechanic.
References
- Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 19 Subsequent Events — Note Purchase Agreement, $4.63 per ADS conversion price — p.226
- Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 3.D Risk Factors — March 11, 2026 Trustar/Huang Note Purchase Agreement and significant-shareholder objection — p.40
- Yatsen Holding Limited — Q1 FY2026 Earnings Release, Operating Expenses and Operating Loss commentary, Douyin traffic-acquisition costs — p.2
- Yatsen Holding Limited — Q4 FY2025 Earnings Release, Out-of-Period Adjustment footnote — p.9
- Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 5 MD&A — Segment income/(loss) from operations: Color Cosmetics -¥59M, Skincare -¥31M FY2025 — p.127
- Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 7 Related Party Transactions — escalating purchases from CEO-controlled affiliates ¥211M → ¥286M → ¥372M — p.147
- Yatsen Holding Limited — Q4 FY2025 Earnings Release, Consolidated Balance Sheets — cash + ST investments and accumulated deficit — p.8
- Proya Cosmetics Co., Ltd. — FY2025 Annual Report, Management Discussion / Brand Portfolio and operating-margin disclosure — p.11